Phase3 Study of DE-114A Ophthalmic Solution in Patients With Allergic Conjunctivitis

Double-masked, Comparison Study of DE-114A Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study -

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223524

Enrollment

Registered

2017-05-15

Start date

2017-05-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Interventions

investigational material(s) Generic name etc : DE-114A ophthalmic solution INN of investigational material : Epinastine Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administrat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Provided signed, written informed consent. Has a positive result from an allergen-specific IgE antibody test.

Exclusion criteria

Exclusion criteria: Eye disease other than allergic conjunctivitis is present and requires treatment. Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.

Design outcomes

Primary

Measure	Time frame
efficacy Mean Ocular Itching Score Mean Hyperemia Score	—

Secondary

Measure	Time frame
efficacy Ocular Itching Score Hyperemia Score	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026